Article Text

Download PDFPDF
Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration
  1. E Rechtman1,2,
  2. R P Danis1,3,
  3. L M Pratt1,
  4. A Harris1
  1. 1Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA
  2. 2Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel
  3. 3Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI, USA
  1. Correspondence to: Dr R P Danis Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Park West One, 406 Science Drive, Suite 400, Madison, WI, 53711-1068, USA; rdanisrc.ophth.wisc.edu; ehudrechtmanyahoo.com

Abstract

Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascularisation (CNV) in age related macular degeneration (AMD).

Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained ⩾15 and ⩾30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed.

Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months (range 12 to 25 months). Overall, 7% gained ⩾30 letters, 50% maintained stable vision, 14% lost 15–29 letters, and 29% lost ⩾30 letters. Overall, mean GLD increased from 2580 (SD 1088) µm to 3946 (SD 1503) µm (p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5% and cataract progression in 50% of phakic eyes.

Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.

  • age related macular degeneration
  • photodynamic therapy
  • verteporfin
  • triamcinolone
  • AMD, age related macular degeneration
  • CNV, choroidal neovascularisation
  • FA, fluorescein angiography
  • GLD, greatest linear dimension
  • iTAAC, intravitreal triamcinolone acetonide
  • PDT, photodynamic therapy
  • VA, visual acuity
  • age related macular degeneration
  • photodynamic therapy
  • verteporfin
  • triamcinolone
  • AMD, age related macular degeneration
  • CNV, choroidal neovascularisation
  • FA, fluorescein angiography
  • GLD, greatest linear dimension
  • iTAAC, intravitreal triamcinolone acetonide
  • PDT, photodynamic therapy
  • VA, visual acuity

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Linked Articles

  • BJO at a glance
    BMJ Publishing Group Ltd.BMA House, Tavistock Square, London, WC1H 9JR